DK1015459T3 - Tetrazol-indeholdende rapamycinanaloger med forkortede halveringstider - Google Patents

Tetrazol-indeholdende rapamycinanaloger med forkortede halveringstider

Info

Publication number
DK1015459T3
DK1015459T3 DK98949512T DK98949512T DK1015459T3 DK 1015459 T3 DK1015459 T3 DK 1015459T3 DK 98949512 T DK98949512 T DK 98949512T DK 98949512 T DK98949512 T DK 98949512T DK 1015459 T3 DK1015459 T3 DK 1015459T3
Authority
DK
Denmark
Prior art keywords
tetrazole
lives
containing rapamycin
rapamycin analogues
shortened half
Prior art date
Application number
DK98949512T
Other languages
English (en)
Inventor
Karl W Mollison
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25470968&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1015459(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK1015459T3 publication Critical patent/DK1015459T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK98949512T 1997-09-26 1998-09-24 Tetrazol-indeholdende rapamycinanaloger med forkortede halveringstider DK1015459T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93814497A 1997-09-26 1997-09-26
PCT/US1998/020111 WO1999015530A1 (en) 1997-09-26 1998-09-24 Tetrazole-containing rapamycin analogs with shortened half-lives

Publications (1)

Publication Number Publication Date
DK1015459T3 true DK1015459T3 (da) 2005-10-10

Family

ID=25470968

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98949512T DK1015459T3 (da) 1997-09-26 1998-09-24 Tetrazol-indeholdende rapamycinanaloger med forkortede halveringstider

Country Status (27)

Country Link
EP (1) EP1015459B9 (da)
JP (1) JP3790424B2 (da)
KR (3) KR100803639B1 (da)
CN (1) CN1161360C (da)
AR (1) AR015940A1 (da)
AT (1) ATE297398T1 (da)
AU (1) AU745576B2 (da)
BG (1) BG64955B1 (da)
BR (1) BR9812305A (da)
CA (1) CA2303934C (da)
CO (1) CO5070656A1 (da)
CZ (1) CZ299365B6 (da)
DE (1) DE69830502T2 (da)
DK (1) DK1015459T3 (da)
ES (1) ES2244087T3 (da)
HU (1) HU228368B1 (da)
IL (2) IL134607A0 (da)
NO (1) NO325813B1 (da)
NZ (2) NZ514778A (da)
PL (1) PL191212B1 (da)
PT (1) PT1015459E (da)
SI (1) SI1015459T1 (da)
SK (1) SK285408B6 (da)
TR (1) TR200000778T2 (da)
TW (1) TW557297B (da)
WO (1) WO1999015530A1 (da)
ZA (1) ZA988750B (da)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7399480B2 (en) 1997-09-26 2008-07-15 Abbott Laboratories Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US7357942B2 (en) * 1997-09-26 2008-04-15 Abbott Laboratories Compositions, systems, and kits for administering zotarolimus and paclitaxel to blood vessel lumens
US7960405B2 (en) 1998-09-24 2011-06-14 Abbott Laboratories Compounds and methods for treatment and prevention of diseases
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20050163781A1 (en) * 2002-01-29 2005-07-28 Philippe Koninckx Tissue adhesion formation control
US20030176455A1 (en) * 2002-03-13 2003-09-18 Wyeth Method of inhibiting cell death
CA2483594C (en) 2002-05-16 2011-02-15 Novartis Ag Use of edg receptor binding agents in cancer
CN100351244C (zh) 2002-05-27 2007-11-28 诺瓦提斯公司 双芳族链烷醇
NZ538568A (en) * 2002-09-06 2010-09-30 Abbott Lab Medical device having hydration inhibitor
MXPA05003254A (es) 2002-09-24 2005-06-08 Novartis Ag Agonistas del receptor de esfingosina-1-fosfato en el tratamiento de trastornos de desmielinacion.
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
AU2004251146A1 (en) 2003-05-19 2005-01-06 Irm, Llc Immunosuppressant compounds and compositions
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2006050461A1 (en) 2004-10-28 2006-05-11 Wyeth Use of an mtor inhibitor in treatment of uterine leiomyoma
GB0504544D0 (en) 2005-03-04 2005-04-13 Novartis Ag Organic compounds
US20090062909A1 (en) 2005-07-15 2009-03-05 Micell Technologies, Inc. Stent with polymer coating containing amorphous rapamycin
KR101406415B1 (ko) 2005-07-15 2014-06-19 미셀 테크놀로지즈, 인코포레이티드 제어된 형태의 약물 분말을 함유하는 중합체 코팅
EP2295080A3 (en) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
BRPI0617057A2 (pt) 2005-08-30 2011-07-12 Univ Miami anticorpo isolado, toxina especìfica para receptor de fator de necrose tumoral 25 (tnfr25), método para ativar o receptor de fator de necrose tumoral 25 (tnfr25), método para inibir a sinalização do receptor de fator de necrose tumoral 25 (tnfr25) numa célula, vacina antitumoral, método para imunizar um paciente contra tumor, método para tratar cáncer num paciente, método para tratar e/ou prevenir inflamação intestinal, composição terapêutica para a facilitação de um transplante de órgão, método para transplantar um tecido de um doador para um hospedeiro, método para inibir a expressão clonal de uma população de células t cd8 cognatas, método para tratar e/ou prevenir inflamação pulmonar, antagonista de tnfr25 isolado, composição e vetor de expressão
BRPI0618042A2 (pt) 2005-11-04 2011-08-16 Wyeth Corp usos de uma rapamicina e de uma herceptina, produto, pacote farmacêutico, e, composição farmacêutica
US7700614B2 (en) * 2005-12-14 2010-04-20 Abbott Laboratories One pot synthesis of tetrazole derivatives of rapamycin
CA2996768C (en) 2006-04-26 2020-12-08 Micell Technologies, Inc. Coatings containing multiple drugs
US7820812B2 (en) 2006-07-25 2010-10-26 Abbott Laboratories Methods of manufacturing crystalline forms of rapamycin analogs
US7812032B2 (en) 2006-07-25 2010-10-12 Abbott Laboratories Crystalline forms of rapamycin analogs
BRPI0714945B8 (pt) * 2006-07-25 2021-05-25 Abbott Lab composições de análogo de rapamicina e processos para preparação de formas cristalinas de análogos de rapamicinas
CN101711137B (zh) 2007-01-08 2014-10-22 米歇尔技术公司 具有可生物降解层的支架
US11426494B2 (en) 2007-01-08 2022-08-30 MT Acquisition Holdings LLC Stents having biodegradable layers
TW200901989A (en) 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US9433516B2 (en) 2007-04-17 2016-09-06 Micell Technologies, Inc. Stents having controlled elution
EP2278966B1 (en) 2008-03-21 2019-10-09 The University of Chicago Treatment with opioid antagonists and mtor inhibitors
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
JP5608160B2 (ja) 2008-04-17 2014-10-15 ミセル テクノロジーズ、インコーポレイテッド 生体吸収性の層を有するステント
KR20180017232A (ko) 2008-06-20 2018-02-20 노파르티스 아게 다발성 경화증을 치료하기 위한 소아용 조성물
EP2313122B1 (en) 2008-07-17 2019-03-06 Micell Technologies, Inc. Drug delivery medical device
RS53041B (sr) 2008-12-18 2014-04-30 Novartis Ag Hemifumaratna so 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
EP2379499B1 (en) 2008-12-18 2014-04-09 Novartis AG Hydrochloride salt of 1-(4-(1-((E)-4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl)-2-ethyl-benzyl)-azetidine-3-carboxylic acid
AU2009327405A1 (en) 2008-12-18 2011-06-30 Novartis Ag New polymorphic form of 1- (4- { l- [ (E) -4-cyclohexyl--3-trifluoromethyl-benzyloxyimino] -ethyl) -2-ethyl-benzy l) -azetidine-3-carboxylic
JP2012522589A (ja) 2009-04-01 2012-09-27 ミシェル テクノロジーズ，インコーポレイテッド 被覆ステント
EP2453834A4 (en) 2009-07-16 2014-04-16 Micell Technologies Inc MEDICAL DEVICE DISPENSING MEDICINE
DK2462165T3 (da) 2009-08-03 2016-08-29 Univ Miami Fremgangsmåde til in-vivo proliferation af regulatoriske T-celler
CA2777128A1 (en) 2009-10-30 2011-05-05 Ariad Pharmaceuticals, Inc. Methods and compositions for treating cancer
EP2531140B1 (en) 2010-02-02 2017-11-01 Micell Technologies, Inc. Stent and stent delivery system with improved deliverability
CA2789622C (en) * 2010-02-11 2018-04-03 Bristol-Myers Squibb Company Macrocycles as factor xia inhibitors
US10232092B2 (en) 2010-04-22 2019-03-19 Micell Technologies, Inc. Stents and other devices having extracellular matrix coating
MX342590B (es) 2010-04-27 2016-10-05 Roche Glycart Ag Terapia de combinacion de un anticuerpo cd20 afucosilado con un inhibidor mtor.
CN102234288B (zh) * 2010-05-06 2014-07-02 上海医药工业研究院 唑他莫司的制备方法
EP2593039B1 (en) 2010-07-16 2022-11-30 Micell Technologies, Inc. Drug delivery medical device
WO2012112847A1 (en) 2011-02-18 2012-08-23 Novartis Pharma Ag mTOR/JAK INHIBITOR COMBINATION THERAPY
JP2014519813A (ja) 2011-04-25 2014-08-21 オーエスアイ・ファーマシューティカルズ，エルエルシー 癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
CA2841360A1 (en) 2011-07-15 2013-01-24 Micell Technologies, Inc. Drug delivery medical device
SI2766346T1 (sl) 2011-10-14 2017-05-31 Bristol-Myers Squibb Company Substituirane tetrahidroizokinolinske spojine kot faktor xia inhibitorji
US10188772B2 (en) 2011-10-18 2019-01-29 Micell Technologies, Inc. Drug delivery medical device
US9315519B2 (en) 2012-10-12 2016-04-19 Bristol-Myers Squibb Company Guanidine substituted tetrahydroisoquinoline compounds as factor XIa inhibitors
EP2906551B1 (en) 2012-10-12 2018-02-28 Bristol-Myers Squibb Company Crystalline forms of a factor xia inhibitor
WO2014059214A1 (en) 2012-10-12 2014-04-17 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
KR20150003156A (ko) * 2012-11-30 2015-01-08 항조우 질록스 파마 컴퍼니 리니티드 라파마이신 유사체 및 이의 제조 방법
CA2897826C (en) 2013-01-09 2022-09-27 Taylor H. Schreiber Compositions and methods for the regulation of t regulatory cells using tl1a-ig fusion protein
EP2967803B1 (en) 2013-03-12 2023-12-27 Micell Technologies, Inc. Bioabsorbable biomedical implants
EP2978751B1 (en) 2013-03-25 2018-12-05 Bristol-Myers Squibb Company Tetrahydroisoquinolines containing substituted azoles as factor xia inhibitors
EP2996629B1 (en) 2013-05-15 2021-09-22 Micell Technologies, Inc. Bioabsorbable biomedical implants
CN105899232A (zh) 2013-11-13 2016-08-24 诺华股份有限公司 用于增强免疫应答的mTOR抑制剂
CA2931684C (en) 2013-12-19 2024-02-20 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
EP3087101B1 (en) 2013-12-20 2024-06-05 Novartis AG Regulatable chimeric antigen receptor
CN103739616B (zh) * 2013-12-27 2015-12-30 福建省微生物研究所 含噻唑基雷帕霉素类衍生物及其应用
CA2935167C (en) 2014-01-16 2022-02-22 Musc Foundation For Research Development Targeted nanocarriers for the administration of immunosuppressive agents
NO2760821T3 (da) 2014-01-31 2018-03-10
KR20240017118A (ko) 2014-01-31 2024-02-06 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
US20170081411A1 (en) 2014-03-15 2017-03-23 Novartis Ag Regulatable chimeric antigen receptor
WO2015149001A1 (en) 2014-03-27 2015-10-01 The Brigham And Women's Hospital, Inc. Metabolically-activated drug conjugates to overcome resistance in cancer therapy
IL322264A (en) 2014-04-07 2025-09-01 Novartis Ag Cancer treatment using chimeric antigen receptor (CAR) against CD19
CN106659758A (zh) 2014-06-02 2017-05-10 儿童医疗中心有限公司 用于免疫调节的组合物和方法
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
US9777061B2 (en) 2014-07-21 2017-10-03 Novartis Ag Treatment of cancer using a CD33 chimeric antigen receptor
WO2016014530A1 (en) 2014-07-21 2016-01-28 Novartis Ag Combinations of low, immune enhancing. doses of mtor inhibitors and cars
US20170209492A1 (en) 2014-07-31 2017-07-27 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
WO2016025880A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using gfr alpha-4 chimeric antigen receptor
SG11201700770PA (en) 2014-08-19 2017-03-30 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
EP3189047B1 (en) 2014-09-04 2018-12-26 Bristol-Myers Squibb Company Diamide macrocycles that are fxia inhibitors
ES2891332T3 (es) 2014-09-17 2022-01-27 Novartis Ag Direccionamiento a células citotóxicas con receptores quiméricos para la inmunoterapia adoptiva
US9453018B2 (en) 2014-10-01 2016-09-27 Bristol-Myers Squibb Company Pyrimidinones as factor XIa inhibitors
AU2015330898B2 (en) 2014-10-08 2022-03-10 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
AU2016249005B2 (en) 2015-04-17 2022-06-16 Novartis Ag Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
EP3286211A1 (en) 2015-04-23 2018-02-28 Novartis AG Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
EP3297629A1 (en) 2015-05-20 2018-03-28 Novartis AG Pharmaceutical combination of everolimus with dactolisib
CN109069467B (zh) 2015-11-11 2022-11-04 诺华股份有限公司 肌生成抑制蛋白拮抗剂的用途、含有它们的组合及其用途
CN109641947B (zh) 2016-07-20 2023-04-14 犹他大学研究基金会 Cd229 car t细胞及其使用方法
WO2018067992A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
BR112019010470A2 (pt) 2016-11-23 2019-09-10 Novartis Ag métodos de realce de resposta imune com everolimo, dactolisib ou ambos
US20200055948A1 (en) 2017-04-28 2020-02-20 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
US10596165B2 (en) 2018-02-12 2020-03-24 resTORbio, Inc. Combination therapies
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
CN113164557A (zh) 2018-07-23 2021-07-23 因柯利尔疗法公司 治疗神经性病症的方法
CA3107349A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
WO2020210634A1 (en) 2019-04-11 2020-10-15 Enclear Therapies, Inc. Methods of amelioration of cerebrospinal fluid and devices and systems therefor
IL301751A (en) 2020-09-29 2023-05-01 Enclear Therapies Inc Subarachnoid fluid management method and system
JP2023550544A (ja) 2020-11-03 2023-12-01 アールディスカバリー エルエルシー がんおよびファゴサイトーシス不全に関連する疾患の処置のための療法
JP2024529341A (ja) 2021-07-15 2024-08-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 粒子が付着している細胞に関連する組成物および方法
CN116082362B (zh) * 2023-01-04 2024-05-10 山东大学 一种可用于合成靶向抗肿瘤药物的氨甲酰美登醇及其合成方法与应用
GB202415232D0 (en) 2024-10-16 2024-11-27 Nacamed As Composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995014023A1 (en) * 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
CN1235608A (zh) * 1996-09-09 1999-11-17 美国家用产品公司 烷基化的雷帕霉素衍生物
AU4246197A (en) * 1996-09-09 1998-03-26 American Home Products Corporation Rapamycin derivatives with unnatural stereochemistries

Also Published As

Publication number Publication date
JP2001517671A (ja) 2001-10-09
NZ502896A (en) 2001-12-21
HK1030771A1 (en) 2001-05-18
NZ514778A (en) 2005-01-28
CA2303934A1 (en) 1999-04-01
EP1015459B1 (en) 2005-06-08
KR20070086925A (ko) 2007-08-27
SI1015459T1 (en) 2005-10-31
NO20001438L (no) 2000-05-26
WO1999015530A1 (en) 1999-04-01
AU745576B2 (en) 2002-03-21
DE69830502D1 (de) 2005-07-14
HUP0004556A3 (en) 2001-12-28
CZ20001014A3 (cs) 2000-07-12
KR100833812B1 (ko) 2008-05-30
NO20001438D0 (no) 2000-03-20
TR200000778T2 (tr) 2000-07-21
KR20060071092A (ko) 2006-06-26
PL191212B1 (pl) 2006-03-31
KR100803639B1 (ko) 2008-02-19
BR9812305A (pt) 2000-09-05
NO325813B1 (no) 2008-07-21
JP3790424B2 (ja) 2006-06-28
BG64955B1 (bg) 2006-10-31
KR100700319B1 (ko) 2007-03-29
AU9581998A (en) 1999-04-12
CA2303934C (en) 2010-01-26
HUP0004556A2 (hu) 2001-10-28
ZA988750B (en) 1999-04-01
ATE297398T1 (de) 2005-06-15
ES2244087T3 (es) 2005-12-01
CZ299365B6 (cs) 2008-07-02
SK285408B6 (sk) 2007-01-04
BG104316A (en) 2000-12-29
PT1015459E (pt) 2005-09-30
AR015940A1 (es) 2001-05-30
KR20010024298A (ko) 2001-03-26
CO5070656A1 (es) 2001-08-28
DE69830502T2 (de) 2006-05-11
IL134607A (en) 2006-04-10
EP1015459A1 (en) 2000-07-05
PL339455A1 (en) 2000-12-18
CN1271361A (zh) 2000-10-25
IL134607A0 (en) 2001-04-30
CN1161360C (zh) 2004-08-11
TW557297B (en) 2003-10-11
EP1015459B9 (en) 2005-10-12
SK4172000A3 (en) 2000-08-14
HU228368B1 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
NO20001438D0 (no) Tetrazol-inneholdende rapamycin-analoger med forkortet halveringstid
DE69833372D1 (de) Stossdämpfer
EE03801B1 (xx) Stent
FI970468A0 (fi) Anvaendningspraoksberoende bokstavsmatning med nummertangenter
EE9900422A (xx) Stent
EE9900449A (xx) Stent
NO2012005I2 (no) Romiplostim
ID20039A (id) Mikroemulsi
FI974269A0 (fi) Radiosaendare-mottagarestruktur med tvao frekvensomraoden
NO994882D0 (no) Baerelegeme med et beskyttelsesbelegg
NO996354D0 (no) Periferisk virkende anti-pruritiske opiater
DE59809684D1 (de) Stabilisator
DE69831665D1 (de) Stossdämpferbock
ID24343A (id) Perbaikan bagian-bagian struktural
FI972664A0 (fi) Foerseglad saeck med avluftning
DE69827308D1 (de) Stosssensor
DE50000794D1 (de) Federelement
KR970027079U (ko) 자세교정구
FI974544A0 (fi) Anordning i en med manoeverplats foersedd lastkran
FI970405A0 (fi) Plattformad traeprodukt med skiktstruktur
DE69823678D1 (de) Federelement
DK199900019U3 (da) Pilk med flere ophængspunkter
FI970017A0 (fi) Med lampeffekts maetning foersett reglerbart elektroniskt anslutningsorgan
NO970032D0 (no) Stötdemper
BR9702698A (pt) Amortecedore curvo